← Back to patent-cliff list
盐酸布比卡因/枸橼酸芬太尼
Tier C — Watch / tradeBupivacaine Hydrochloride/Fentanyl Citrate
Amco
Originator
2012
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：Opioid receptors、SCNA
Brand：Bufyl
Indications (approved)：疼痛
Regional status
US
-
EU
批准上市
2012-01-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Bupivacaine Hydrochloride/Fentanyl Citrate?
Approved indications include: 疼痛.
When does the Bupivacaine Hydrochloride/Fentanyl Citrate patent expire?
No public expiry year is available for Bupivacaine Hydrochloride/Fentanyl Citrate yet; this page updates once verified.
How do I get a quote for Bupivacaine Hydrochloride/Fentanyl Citrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24